{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:12:42Z","timestamp":1793329962092,"version":"4.5.0"},"reference-count":250,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41581-025-01042-0","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:02:20Z","timestamp":1768208540000},"page":"318-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Next-generation therapeutics for diabetic kidney disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3350-1170","authenticated-orcid":false,"given":"Tae Won","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-5250","authenticated-orcid":false,"given":"Jennifer","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","unstructured":"Duncan, B. B., Magliano, D. J. & Boyko, E. J. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050. Nephrol. Dial. Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaf177 (2025).","DOI":"10.1093\/ndt\/gfaf177"},{"key":"1042_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11892-015-0631-4","volume":"15","author":"BM Popkin","year":"2015","unstructured":"Popkin, B. M. Nutrition transition and the global diabetes epidemic. Curr. Diab Rep. 15, 64 (2015).","journal-title":"Curr. Diab Rep."},{"key":"1042_CR3","unstructured":"International Diabetes Federation IDF Diabetes Atlas 10th edn (International Diabetes Federation, 2021)."},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens, P. E. et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"1042_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye, D. N., Magliano, D. J., Nelson, R. G. & Pavkov, M. E. The global epidemiology of diabetes and kidney disease. Adv. Chronic Kidney Dis. 25, 121\u2013132 (2018).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"1042_CR6","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023 (US Department of Health and Human Services, Centers for Disease Control and Prevention, 2023)."},{"issue":"(4 Suppl. 1)","key":"1042_CR7","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1053\/j.ajkd.2024.01.001","volume":"83","author":"KL Johansen","year":"2024","unstructured":"Johansen, K. L. et al. US Renal Data System 2023 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 83 (4 Suppl. 1), A8\u2013A13 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"1042_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov, B. et al. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 395, 709\u2013733 (2020).","journal-title":"Lancet"},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Diabetic kidney disease: challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12, 2032\u20132045 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1042_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002125","volume":"9","author":"TP Griffin","year":"2021","unstructured":"Griffin, T. P. et al. Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in Northern Europe. BMJ Open. Diabetes Res. Care 9, e002125 (2021).","journal-title":"BMJ Open. Diabetes Res. Care"},{"key":"1042_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065927","volume":"13","author":"S Cook","year":"2023","unstructured":"Cook, S. et al. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the clinical practice research datalink. BMJ Open. 13, e065927 (2023).","journal-title":"BMJ Open."},{"key":"1042_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302\u2013308 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1042_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/kidneydial2030038","volume":"2","author":"EK Hoogeveen","year":"2022","unstructured":"Hoogeveen, E. K. The epidemiology of diabetic kidney disease. Kidney Dialysis 2, 433\u2013442 (2022).","journal-title":"Kidney Dialysis"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer, I. H. et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1\u2013S127 (2022).","journal-title":"Kidney Int."},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ndt\/gfw070","volume":"32","author":"M Fiorentino","year":"2017","unstructured":"Fiorentino, M. et al. Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol. Dial. Transplant. 32, 97\u2013110\u00a0(2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1042_CR16","doi-asserted-by":"publisher","first-page":"672350","DOI":"10.3389\/fendo.2021.672350","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng, Y. et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. Front. Endocrinol. 12, 672350 (2021).","journal-title":"Front. Endocrinol."},{"key":"1042_CR17","doi-asserted-by":"publisher","first-page":"1513008","DOI":"10.3389\/fendo.2025.1513008","volume":"16","author":"X Ma","year":"2025","unstructured":"Ma, X., Liu, R., Xi, X., Zhuo, H. & Gu, Y. Global burden of chronic kidney disease due to diabetes mellitus, 1990-2021, and projections to 2050. Front. Endocrinol. 16, 1513008 (2025).","journal-title":"Front. Endocrinol."},{"key":"1042_CR18","doi-asserted-by":"publisher","unstructured":"Xie, M., Wu, J. & Wang, P. Global burden of chronic kidney disease and diabetic kidney disease in 204 countries and territories from 1990 to 2021: results from the Global Burden of Disease Study 2021. Preprint at SSRN https:\/\/doi.org\/10.2139\/ssrn.5083847 (2025).","DOI":"10.2139\/ssrn.5083847"},{"key":"1042_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis, A. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat. Rev. Nephrol. 20, 473\u2013485 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR20","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas, M. C. et al. Diabetic kidney disease. Nat. Rev. Dis. Primers 1, 15018 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1042_CR21","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes \u2014 2025. Diabetes Care 48, S239\u2013S251 (2024).","journal-title":"Diabetes Care"},{"key":"1042_CR22","unstructured":"WHO. Noncommunicable Disease Facility-Based Monitoring Guidance: Framework, Indicators and Application (World Health Organization, 2022)."},{"key":"1042_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle, K. R. et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 102, 248\u2013260 (2022).","journal-title":"Kidney Int."},{"key":"1042_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2018.9","volume":"14","author":"JM Forbes","year":"2018","unstructured":"Forbes, J. M. & Thorburn, D. R. Mitochondrial dysfunction in diabetic kidney disease. Nat. Rev. Nephrol. 14, 291\u2013312 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","volume":"19","author":"A Mitrofanova","year":"2023","unstructured":"Mitrofanova, A., Merscher, S. & Fornoni, A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat. Rev. Nephrol. 19, 629\u2013645 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR26","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1016\/j.ekir.2024.09.019","volume":"9","author":"P Narongkiatikhun","year":"2024","unstructured":"Narongkiatikhun, P. et al. Unraveling diabetic kidney disease: the roles of mitochondrial dysfunction and immunometabolism. Kidney Int. Rep. 9, 3386\u20133402 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.cmet.2020.10.019","volume":"32","author":"Y Fu","year":"2020","unstructured":"Fu, Y. et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism. Cell Metab. 32, 1052\u20131062.e8 (2020).","journal-title":"Cell Metab."},{"key":"1042_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.kint.2022.06.010","volume":"102","author":"K Shahzad","year":"2022","unstructured":"Shahzad, K. et al. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. Kidney Int. 102, 766\u2013779 (2022).","journal-title":"Kidney Int."},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.kint.2024.04.011","volume":"106","author":"Y Feng","year":"2024","unstructured":"Feng, Y. et al. Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury. Kidney Int. 106, 50\u201366 (2024).","journal-title":"Kidney Int."},{"key":"1042_CR30","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00125-024-06191-8","volume":"67","author":"M Wu","year":"2024","unstructured":"Wu, M. et al. The role of PCSK9 in glomerular lipid accumulation and renal injury in diabetic kidney disease. Diabetologia 67, 1980\u20131997 (2024).","journal-title":"Diabetologia"},{"key":"1042_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49854-1","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Podocyte OTUD5 alleviates diabetic kidney disease through deubiquitinating TAK1 and reducing podocyte inflammation and injury. Nat. Commun. 15, 5441 (2024).","journal-title":"Nat. Commun."},{"key":"1042_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","volume":"114","author":"A Goldin","year":"2006","unstructured":"Goldin, A., Beckman, J. A., Schmidt, A. M. & Creager, M. A. Advanced glycation end products. Circulation 114, 597\u2013605 (2006).","journal-title":"Circulation"},{"key":"1042_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41581-024-00907-0","volume":"21","author":"AB Fogo","year":"2025","unstructured":"Fogo, A. B. & Harris, R. C. Crosstalk between glomeruli and tubules. Nat. Rev. Nephrol. 21, 189\u2013199 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","volume":"98","author":"AC Hesp","year":"2020","unstructured":"Hesp, A. C. et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 98, 579\u2013589 (2020).","journal-title":"Kidney Int."},{"key":"1042_CR35","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456\u20131462 (1993).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851\u2013860 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington, W. G. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117\u2013127 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR39","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR40","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR41","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129\u2013139 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR44","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent, C. et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788\u20131801 (2022).","journal-title":"Lancet"},{"key":"1042_CR45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer, I. H. et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 102, 974\u2013989 (2022).","journal-title":"Kidney Int."},{"key":"1042_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.kisu.2017.10.005","volume":"8","author":"DZI Cherney","year":"2018","unstructured":"Cherney, D. Z. I. & Bakris, G. L. Novel therapies for diabetic kidney disease. Kidney Int. Suppl. 8, 18\u201325 (2018).","journal-title":"Kidney Int. Suppl."},{"key":"1042_CR47","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt, B. et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34, 2453\u20132463 (2013).","journal-title":"Eur. Heart J."},{"key":"1042_CR48","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263\u00a0(2021).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR49","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776\u2013785 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR50","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Frias","year":"2016","unstructured":"Frias, J. P. et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 4, 1004\u20131016 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","volume":"6","author":"B Ludvik","year":"2018","unstructured":"Ludvik, B. et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 370\u2013381 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR52","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman, B. et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 7, 356\u2013367 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","volume":"18","author":"LE Clegg","year":"2019","unstructured":"Clegg, L. E. et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc. Diabetol. 18, 138 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"1042_CR54","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. 30, 2849\u20132856 (2024).","journal-title":"Nat. Med."},{"key":"1042_CR55","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo, E. M. et al. Apperloo, E. M. et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 12, 545\u2013557 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR56","doi-asserted-by":"publisher","first-page":"ehaa946.0939","DOI":"10.1093\/ehjci\/ehaa946.0939","volume":"41","author":"SL Kristensen","year":"2020","unstructured":"Kristensen, S. L. et al. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. Eur. Heart J. 41, ehaa946.0939 (2020).","journal-title":"Eur. Heart J."},{"key":"1042_CR57","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen, B. L. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145, 1460\u20131470 (2022).","journal-title":"Circulation"},{"key":"1042_CR58","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2023.04.015","volume":"82","author":"RB Albakr","year":"2023","unstructured":"Albakr, R. B., Sridhar, V. S. & Cherney, D. Z. I. Novel therapies in diabetic kidney disease and risk of hyperkalemia: a review of the evidence from clinical trials. Am. J. Kidney Dis. 82, 737\u2013742 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"1042_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int. Rep. 7, 36\u201345 (2022).","journal-title":"Kidney Int. Rep."},{"key":"1042_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","volume":"151","author":"M Vaduganathan","year":"2025","unstructured":"Vaduganathan, M. et al. Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation 151, 149\u2013158 (2025).","journal-title":"Circulation"},{"key":"1042_CR61","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal, R. et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N. Engl. J. Med. 393, 1755 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR62","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2014070688","volume":"26","author":"HJ Lambers Heerspink","year":"2015","unstructured":"Lambers Heerspink, H. J., Kr\u00f6pelin, T. F., Hoekman, J. & de Zeeuw, D. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J. Am. Soc. Nephrol. 26, 2055 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1042_CR63","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030131","volume":"13","author":"JI Barzilay","year":"2024","unstructured":"Barzilay, J. I., Farag, Y. M. K. & Durthaler, J. Albuminuria: an underappreciated risk factor for cardiovascular disease. J. Am. Heart Assoc. 13, e030131 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1042_CR64","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2337\/dc20-1622","volume":"44","author":"F Persson","year":"2021","unstructured":"Persson, F. et al. Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial. Diabetes Care 44, 1020\u20131026 (2021).","journal-title":"Diabetes Care"},{"key":"1042_CR65","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L. et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 149, 450\u2013462 (2024).","journal-title":"Circulation"},{"key":"1042_CR66","doi-asserted-by":"publisher","first-page":"sfad285","DOI":"10.1093\/ckj\/sfad285","volume":"17","author":"JJ Neumiller","year":"2024","unstructured":"Neumiller, J. J., Alicic, R. Z. & Tuttle, K. R. Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease. Clin. Kidney J. 17, sfad285 (2024).","journal-title":"Clin. Kidney J."},{"key":"1042_CR67","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L., Tuttle, K. R. & Vaduganathan, M. Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease. Circulation 149, 1238\u20131240 (2024).","journal-title":"Circulation"},{"key":"1042_CR68","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium\u2013glucose cotransporter 2 inhibitor treatment: the fidelity analysis. Diabetes Care 45, 2991\u20132998 (2022).","journal-title":"Diabetes Care"},{"key":"1042_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"Cherney, D. Z. I. et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 93, 231\u2013244 (2018).","journal-title":"Kidney Int."},{"key":"1042_CR70","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ekir.2022.07.167","volume":"7","author":"DZI Cherney","year":"2022","unstructured":"Cherney, D. Z. I. et al. Hemoglobin A1c reduction with the GLP-1 receptor agonist semaglutide is independent of baseline eGFR: post hoc analysis of the sustain and pioneer programs. Kidney Int. Rep. 7, 2345\u20132355 (2022).","journal-title":"Kidney Int. Rep."},{"key":"1042_CR71","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/dom.14108","volume":"22","author":"C Mantsiou","year":"2020","unstructured":"Mantsiou, C. et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes, Obes. Metab. 22, 1857\u20131868 (2020).","journal-title":"Diabetes, Obes. Metab."},{"key":"1042_CR72","doi-asserted-by":"publisher","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","volume":"17","author":"FH M\u00e5rup","year":"2024","unstructured":"M\u00e5rup, F. H., Thomsen, M. B. & Birn, H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin. Kidney J. 17, sfad249 (2024).","journal-title":"Clin. Kidney J."},{"key":"1042_CR73","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano, M. et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J. Am. Soc. Nephrol. 33, 1569 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1042_CR74","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/dom.15033","volume":"25","author":"AB van der Aart-van der Beek","year":"2023","unstructured":"van der Aart-van der Beek, A. B. et al. Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: a randomized cross-over clinical study. Diabetes, Obes. Metab. 25, 1758\u20131768 (2023).","journal-title":"Diabetes, Obes. Metab."},{"key":"1042_CR75","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","volume":"141","author":"CP Cannon","year":"2020","unstructured":"Cannon, C. P. et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%. Circulation 141, 407\u2013410 (2020).","journal-title":"Circulation"},{"key":"1042_CR76","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2337\/dc19-2251","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse, J. B. et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the leader trial. Diabetes Care 43, 1546\u20131552 (2020).","journal-title":"Diabetes Care"},{"key":"1042_CR77","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1002\/ehf2.13615","volume":"8","author":"D Fitchett","year":"2021","unstructured":"Fitchett, D. et al. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG outcome trial. ESC Heart Fail. 8, 4517\u20134527 (2021).","journal-title":"ESC Heart Fail."},{"key":"1042_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01386-4","volume":"20","author":"M Konig","year":"2021","unstructured":"Konig, M. et al. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovasc. Diabetol. 20, 194 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"1042_CR79","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc24-0764","volume":"47","author":"I Lingvay","year":"2024","unstructured":"Lingvay, I. et al. Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in select. Diabetes Care 47, 1360\u20131369 (2024).","journal-title":"Diabetes Care"},{"key":"1042_CR80","doi-asserted-by":"publisher","unstructured":"Neuen, B. L. et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA https:\/\/doi.org\/10.1001\/jama.2025.20834 (2025).","DOI":"10.1001\/jama.2025.20834"},{"key":"1042_CR81","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. I. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation 134, 752\u2013772 (2016).","journal-title":"Circulation"},{"key":"1042_CR82","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","volume":"59","author":"L Tonneijck","year":"2016","unstructured":"Tonneijck, L. et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia 59, 1412\u20131421 (2016).","journal-title":"Diabetologia"},{"key":"1042_CR83","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.2337\/dc16-1371","volume":"39","author":"L Tonneijck","year":"2016","unstructured":"Tonneijck, L. et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 39, 2042\u20132050 (2016).","journal-title":"Diabetes Care"},{"key":"1042_CR84","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605\u2013628 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR85","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke, C. et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280\u20131290 (2014).","journal-title":"Endocrinology"},{"key":"1042_CR86","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"104","author":"AC Schoolwerth","year":"2001","unstructured":"Schoolwerth, A. C., Sica, D. A., Ballermann, B. J. & Wilcox, C. S. Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation 104, 1985\u20131991 (2001).","journal-title":"Circulation"},{"key":"1042_CR87","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp, F. A. et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 80, 282\u2013287 (2011).","journal-title":"Kidney Int."},{"key":"1042_CR88","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","volume":"108","author":"SD Navaneethan","year":"2025","unstructured":"Navaneethan, S. D. et al. Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis. Kidney Int. 108, 136\u2013144 (2025).","journal-title":"Kidney Int."},{"key":"1042_CR89","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1161\/01.CIR.94.12.3271","volume":"94","author":"PV Prasad","year":"1996","unstructured":"Prasad, P. V., Edelman, R. R. & Epstein, F. H. Noninvasive evaluation of intrarenal oxygenation with BOLD MRI. Circulation 94, 3271\u20133275 (1996).","journal-title":"Circulation"},{"key":"1042_CR90","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.2337\/dc24-2244","volume":"48","author":"EM Apperloo","year":"2025","unstructured":"Apperloo, E. M. et al. Exploring kidney oxygenation responses to dapagliflozin, exenatide, and their combination in patients with type 2 diabetes and chronic kidney disease: observations from a prespecified pilot study of a randomized crossover trial. Diabetes Care 48, e22\u2013e24 (2025).","journal-title":"Diabetes Care"},{"key":"1042_CR91","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","volume":"66","author":"S Gullaksen","year":"2023","unstructured":"Gullaksen, S. et al. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia 66, 813\u2013825 (2023).","journal-title":"Diabetologia"},{"key":"1042_CR92","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04865770 (2025)."},{"key":"1042_CR93","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05536804 (2025)."},{"key":"1042_CR94","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123130","volume":"4","author":"S Osataphan","year":"2019","unstructured":"Osataphan, S. et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight 4, e123130 (2019).","journal-title":"JCI Insight"},{"key":"1042_CR95","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00125-023-06078-0","volume":"67","author":"M Shao","year":"2024","unstructured":"Shao, M. et al. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns. Diabetologia 67, 738\u2013754 (2024).","journal-title":"Diabetologia"},{"key":"1042_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129034","volume":"5","author":"J Li","year":"2020","unstructured":"Li, J. et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight 5, e129034 (2020).","journal-title":"JCI Insight"},{"key":"1042_CR97","doi-asserted-by":"publisher","first-page":"771","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay, A. SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360 5, 771 (2024).","journal-title":"Kidney360"},{"key":"1042_CR98","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer, M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation 146, 1383\u20131405 (2022).","journal-title":"Circulation"},{"key":"1042_CR99","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.ekir.2021.05.022","volume":"6","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. Markers of kidney injury, inflammation, and fibrosis associated with ertugliflozin in patients with CKD and diabetes. Kidney Int. Rep. 6, 2095\u20132104 (2021).","journal-title":"Kidney Int. Rep."},{"key":"1042_CR100","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605\u2013617 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR101","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S2213-8587(18)30125-6","volume":"6","author":"DZI Cherney","year":"2018","unstructured":"Cherney, D. Z. I., Verma, S. & Parker, J. D. Dulaglutide and renal protection in type 2 diabetes. Lancet Diabetes Endocrinol. 6, 588\u2013590 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174715","volume":"918","author":"E Abdollahi","year":"2022","unstructured":"Abdollahi, E. et al. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages. Eur. J. Pharmacol. 918, 174715 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"1042_CR103","doi-asserted-by":"publisher","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","volume":"325","author":"X Chen","year":"2023","unstructured":"Chen, X., Hocher, C.-F., Shen, L., Kr\u00e4mer, B. K. & Hocher, B. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench. Am. J. Physiol. Cell Physiol. 325, C661\u2013C681 (2023).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1042_CR104","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","volume":"54","author":"R Kodera","year":"2011","unstructured":"Kodera, R. et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54, 965\u2013978 (2011).","journal-title":"Diabetologia"},{"key":"1042_CR105","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","volume":"61","author":"H Hendarto","year":"2012","unstructured":"Hendarto, H. et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 61, 1422\u20131434 (2012).","journal-title":"Metabolism"},{"key":"1042_CR106","doi-asserted-by":"publisher","first-page":"R410","DOI":"10.1152\/ajpregu.00083.2024","volume":"327","author":"L Huang","year":"2024","unstructured":"Huang, L., Lin, T., Shi, M. & Wu, P. Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4\/MyD88\/NF-\u03baB pathway in diabetic kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 327, R410\u2013R422 (2024).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1042_CR107","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.orcp.2019.03.003","volume":"13","author":"Y Ye","year":"2019","unstructured":"Ye, Y., Zhong, X., Li, N. & Pan, T. Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-\u03b1-mediated NF-\u03baB and MAPK pathway. Obes. Res. Clin. Pract. 13, 385\u2013390 (2019).","journal-title":"Obes. Res. Clin. Pract."},{"key":"1042_CR108","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris, K. C. et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 105, 132\u2013149 (2024).","journal-title":"Kidney Int."},{"key":"1042_CR109","doi-asserted-by":"publisher","first-page":"F556","DOI":"10.1152\/ajprenal.00332.2016","volume":"312","author":"M Bai","year":"2017","unstructured":"Bai, M. et al. NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. Am. J. Physiol. Renal Physiol. 312, F556\u2013F564 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1042_CR110","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira, N. S., Tostes, R. C., Paradis, P. & Schiffrin, E. L. Aldosterone, inflammation, immune system, and hypertension. Am. J. Hypertens. 34, 15\u201327 (2021).","journal-title":"Am. J. Hypertens."},{"key":"1042_CR111","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","volume":"79","author":"Y Maeoka","year":"2022","unstructured":"Maeoka, Y. et al. Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone. Hypertension 79, 1423\u20131434 (2022).","journal-title":"Hypertension"},{"key":"1042_CR112","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal, J. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344\u20131355 (2018).","journal-title":"Kidney Int."},{"key":"1042_CR113","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. results of a randomized controlled trial with Col4a3\u2212\/\u2212 mice. J. Am. Soc. Nephrol. 34, 1513\u20131520 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1042_CR114","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof, P. et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52, 642\u2013652 (2021).","journal-title":"Am. J. Nephrol."},{"key":"1042_CR115","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.kint.2022.10.030","volume":"103","author":"S Rayego-Mateos","year":"2023","unstructured":"Rayego-Mateos, S. et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 103, 282\u2013296 (2023).","journal-title":"Kidney Int."},{"key":"1042_CR116","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41581-025-00934-5","volume":"21","author":"L Abbad","year":"2025","unstructured":"Abbad, L., Esteve, E. & Chatziantoniou, C. Advances and challenges in kidney fibrosis therapeutics. Nat. Rev. Nephrol. 21, 314\u2013329 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR117","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","volume":"49","author":"E Melson","year":"2024","unstructured":"Melson, E., Ashraf, U., Papamargaritis, D. & Davies, M. J. What is the pipeline for future medications for obesity? Int. J. Obes. 49, 433\u2013451 (2024).","journal-title":"Int. J. Obes."},{"key":"1042_CR118","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","volume":"20","author":"S Ansari","year":"2024","unstructured":"Ansari, S., Khoo, B. & Tan, T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 20, 447\u2013459 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1042_CR119","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409\u20131439 (2007).","journal-title":"Physiol. Rev."},{"key":"1042_CR120","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D. J. The biology of incretin hormones. Cell Metab. 3, 153\u2013165 (2006).","journal-title":"Cell Metab."},{"key":"1042_CR121","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/nep.14336","volume":"29","author":"P Trevella","year":"2024","unstructured":"Trevella, P., Ekinci, E. I. & MacIsaac, R. J. Potential kidney protective effects of glucagon-like peptide-1 receptor agonists. Nephrology 29, 457\u2013469 (2024).","journal-title":"Nephrology"},{"key":"1042_CR122","doi-asserted-by":"publisher","first-page":"111905","DOI":"10.1016\/j.diabres.2024.111905","volume":"217","author":"N Rabbani","year":"2024","unstructured":"Rabbani, N. & Thornalley, P. J. Unraveling the impaired incretin effect in obesity and type 2 diabetes: key role of hyperglycemia-induced unscheduled glycolysis and glycolytic overload. Diabetes Res. Clin. Pract. 217, 111905 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1042_CR123","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","volume":"133","author":"TB Usdin","year":"1993","unstructured":"Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J. & Bonner, T. I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133, 2861\u20132870 (1993).","journal-title":"Endocrinology"},{"key":"1042_CR124","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Pfeiffer, A. F. H. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes. Metab. 23, 5\u201329 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"1042_CR125","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201\u2013216 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1042_CR126","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR127","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the surpass-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774\u2013785 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR128","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05556512 (2025)."},{"key":"1042_CR129","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N. Engl. J. Med. 389, 514\u2013526 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR130","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock, J. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402, 529\u2013544 (2023).","journal-title":"Lancet"},{"key":"1042_CR131","doi-asserted-by":"publisher","DOI":"10.2337\/db24-754-P","volume":"73","author":"HL HEERSPINK","year":"2024","unstructured":"HEERSPINK, H. L. et al. 754-P: effect of retatrutide on kidney parameters in people with type 2 diabetes and\/or obesity \u2014 a post-hoc analysis of two phase 2 trials. Diabetes 73, 754-P (2024).","journal-title":"Diabetes"},{"key":"1042_CR132","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06383390 (2025)."},{"key":"1042_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2020.170366","volume":"132","author":"L Boccia","year":"2020","unstructured":"Boccia, L. et al. Amylin brain circuitry. Peptides 132, 170366 (2020).","journal-title":"Peptides"},{"key":"1042_CR134","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"DL Hay","year":"2015","unstructured":"Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G. & Roth, J. D. Amylin: pharmacology, physiology, and clinical potential. Pharmacol. Rev. 67, 564\u2013600 (2015).","journal-title":"Pharmacol. Rev."},{"key":"1042_CR135","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06131372 (2025)."},{"key":"1042_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05669755 (2025)."},{"key":"1042_CR137","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1113\/jphysiol.2008.164269","volume":"587","author":"E Karra","year":"2009","unstructured":"Karra, E., Chandarana, K. & Batterham, R. L. The role of peptide YY in appetite regulation and obesity. J. Physiol. 587, 19\u201325 (2009).","journal-title":"J. Physiol."},{"key":"1042_CR138","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1389450053174523","volume":"6","author":"D Renshaw","year":"2005","unstructured":"Renshaw, D. & Batterham, R. L. Peptide YY: a potential therapy for obesity. Curr. Drug. Targets 6, 171\u2013179 (2005).","journal-title":"Curr. Drug. Targets"},{"key":"1042_CR139","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.peptides.2017.11.005","volume":"100","author":"RA Lafferty","year":"2018","unstructured":"Lafferty, R. A., Flatt, P. R. & Irwin, N. Emerging therapeutic potential for peptide YY for obesity-diabetes. Peptides 100, 269\u2013274 (2018).","journal-title":"Peptides"},{"key":"1042_CR140","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1056\/NEJMoa030204","volume":"349","author":"RL Batterham","year":"2003","unstructured":"Batterham, R. L. et al. Inhibition of food intake in obese subjects by peptide YY3\u201336. N. Engl. J. Med. 349, 941\u2013948 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR141","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/dom.14358","volume":"23","author":"TM-M Tan","year":"2021","unstructured":"Tan, T. M.-M. et al. Safety and efficacy of an extended-release peptide YY analogue for obesity: a randomized, placebo-controlled, phase 1 trial. Diabetes Obes. Metab. 23, 1471\u20131483 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"1042_CR142","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/oby.24329","volume":"33","author":"BS Wulff","year":"2025","unstructured":"Wulff, B. S. et al. Long-acting PYY3\u221236 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies. Obesity 33, 1457\u20131474 (2025).","journal-title":"Obesity"},{"key":"1042_CR143","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells12101419","volume":"12","author":"L Arceri","year":"2023","unstructured":"Arceri, L., Nguyen, T. K., Gibson, S., Baker, S. & Wingert, R. A. Cannabinoid signaling in kidney disease. Cells 12, 1419 (2023).","journal-title":"Cells"},{"key":"1042_CR144","doi-asserted-by":"publisher","first-page":"720734","DOI":"10.3389\/fendo.2021.720734","volume":"12","author":"M Dao","year":"2021","unstructured":"Dao, M. & Fran\u00e7ois, H. Cannabinoid receptor 1 inhibition in chronic kidney disease: a new therapeutic toolbox. Front. Endocrinol. 12, 720734 (2021).","journal-title":"Front. Endocrinol."},{"key":"1042_CR145","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"J-P Despr\u00e9s","year":"2005","unstructured":"Despr\u00e9s, J.-P., Golay, A. & Sj\u00f6str\u00f6m, L. Rimonabant in obesity-lipids study group. effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121\u20132134 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR146","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal, L. F. et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389\u20131397 (2005).","journal-title":"Lancet"},{"key":"1042_CR147","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/d41586-025-00404-9","volume":"638","author":"E Dolgin","year":"2025","unstructured":"Dolgin, E. Dozens of new obesity drugs are coming: these are the ones to watch. Nature 638, 308\u2013310 (2025).","journal-title":"Nature"},{"key":"1042_CR148","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S2213-8587(25)00216-5","volume":"13","author":"FK Knop","year":"2025","unstructured":"Knop, F. K. et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Lancet Diabetes Endocrinol. 13, 911\u2013923 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR149","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/ki.2014.143","volume":"86","author":"DE Kohan","year":"2014","unstructured":"Kohan, D. E. & Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86, 896\u2013904 (2014).","journal-title":"Kidney Int."},{"key":"1042_CR150","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semnephrol.2015.02.002","volume":"35","author":"JJ Maguire","year":"2015","unstructured":"Maguire, J. J. & Davenport, A. P. Endothelin receptors and their antagonists. Semin. Nephrol. 35, 125\u2013136 (2015).","journal-title":"Semin. Nephrol."},{"key":"1042_CR151","doi-asserted-by":"publisher","first-page":"R388","DOI":"10.1152\/ajpregu.00478.2015","volume":"310","author":"A Czopek","year":"2016","unstructured":"Czopek, A., Moorhouse, R., Webb, D. J. & Dhaun, N. Therapeutic potential of endothelin receptor antagonism in kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol 310, R388\u2013R397 (2016).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol"},{"key":"1042_CR152","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.3390\/ijms25126661","volume":"25","author":"G Gallo","year":"2024","unstructured":"Gallo, G. & Savoia, C. Hypertension and heart failure: from pathophysiology to treatment. Int. J. Mol. Sci. 25, 6661 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 3","key":"1042_CR153","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2362.2006.01689.x","volume":"36","author":"W Neuhofer","year":"2006","unstructured":"Neuhofer, W. & Pittrow, D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur. J. Clin. Invest. 36 (Suppl. 3), 78\u201388 (2006).","journal-title":"Eur. J. Clin. Invest."},{"key":"1042_CR154","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","volume":"5","author":"M Packer","year":"2017","unstructured":"Packer, M. et al. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the enable trials. JACC Heart Fail. 5, 317\u2013326 (2017).","journal-title":"JACC Heart Fail."},{"key":"1042_CR155","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/ndt\/gfae214","volume":"40","author":"E Moedt","year":"2025","unstructured":"Moedt, E., Wasehuus, V. S. & Heerspink, H. J. L. Selective endothelin a receptor antagonism in chronic kidney disease: improving clinical application. Nephrol. Dial. Transplant. 40, i37\u2013i46 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1042_CR156","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","volume":"21","author":"JFE Mann","year":"2010","unstructured":"Mann, J. F. E. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527\u2013535 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1042_CR157","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937\u20131947 (2019).","journal-title":"Lancet"},{"key":"1042_CR158","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004\u20132017 (2023).","journal-title":"Lancet"},{"key":"1042_CR159","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06087835 (2025)."},{"key":"1042_CR160","doi-asserted-by":"publisher","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","volume":"326","author":"S Verma","year":"2024","unstructured":"Verma, S. et al. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease. Am. J. Physiol. Heart Circ. Physiol 326, H670\u2013H688 (2024).","journal-title":"Am. J. Physiol. Heart Circ. Physiol"},{"key":"1042_CR161","doi-asserted-by":"publisher","unstructured":"Judge, P. K. et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-kidney trial. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfae263 (2024).","DOI":"10.1093\/ndt\/gfae263"},{"key":"1042_CR162","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","volume":"68","author":"G Remuzzi","year":"2005","unstructured":"Remuzzi, G., Perico, N., Macia, M. & Ruggenenti, P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 68, S57\u2013S65 (2005).","journal-title":"Kidney Int."},{"key":"1042_CR163","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1161\/HYPERTENSIONAHA.108.117044","volume":"52","author":"J D\u00edez","year":"2008","unstructured":"D\u00edez, J. Effects of aldosterone on the heart: beyond systemic hemodynamics? Hypertension 52, 462\u2013464 (2008).","journal-title":"Hypertension"},{"key":"1042_CR164","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","volume":"6","author":"M Briet","year":"2010","unstructured":"Briet, M. & Schiffrin, E. L. Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 6, 261\u2013273 (2010).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR165","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","volume":"29","author":"M Frimodt-M\u00f8ller","year":"2020","unstructured":"Frimodt-M\u00f8ller, M., Persson, F. & Rossing, P. Mitigating risk of aldosterone in diabetic kidney disease. Curr. Opin. Nephrol. Hypertens. 29, 145\u2013151 (2020).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1042_CR166","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1159\/000542621","volume":"49","author":"A Mazzieri","year":"2024","unstructured":"Mazzieri, A. et al. Aldosterone synthase inhibitors for cardiorenal protection: ready for prime time? Kidney Blood Press. Res. 49, 1041\u20131056 (2024).","journal-title":"Kidney Blood Press. Res."},{"key":"1042_CR167","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. & Parving, H.-H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28, 2106\u20132112 (2005).","journal-title":"Diabetes Care"},{"key":"1042_CR168","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","volume":"56","author":"MG Saklayen","year":"2008","unstructured":"Saklayen, M. G., Gyebi, L. K., Tasosa, J. & Yap, J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J. Investig. Med. 56, 714\u2013719 (2008).","journal-title":"J. Investig. Med."},{"key":"1042_CR169","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","volume":"30","author":"FDR Hobbs","year":"2024","unstructured":"Hobbs, F. D. R. et al. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat. Med. 30, 3634\u20133645 (2024).","journal-title":"Nat. Med."},{"key":"1042_CR170","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 403, 379\u2013390 (2024).","journal-title":"Lancet"},{"key":"1042_CR171","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman, M. W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Engl. J. Med. 388, 395\u2013405 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06268873 (2025)."},{"key":"1042_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06742723 (2025)."},{"key":"1042_CR174","doi-asserted-by":"publisher","first-page":"F671","DOI":"10.1152\/ajprenal.00042.2016","volume":"311","author":"K Shen","year":"2016","unstructured":"Shen, K., Johnson, D. W. & Gobe, G. C. The role of cGMP and its signaling pathways in kidney disease. Am. J. Physiol. Renal Physiol 311, F671\u2013F681 (2016).","journal-title":"Am. J. Physiol. Renal Physiol"},{"key":"1042_CR175","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/ki.1996.256","volume":"49","author":"C Baylis","year":"1996","unstructured":"Baylis, C. & Qiu, C. Importance of nitric oxide in the control of renal hemodynamics. Kidney Int. 49, 1727\u20131731 (1996).","journal-title":"Kidney Int."},{"key":"1042_CR176","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/ijms19061712","volume":"19","author":"SM Krishnan","year":"2018","unstructured":"Krishnan, S. M., Kraehling, J. R., Eitner, F., B\u00e9nardeau, A. & Sandner, P. The impact of the nitric oxide (NO)\/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective. Int. J. Mol. Sci. 19, 1712 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1042_CR177","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.800292","volume":"119","author":"H Lapp","year":"2009","unstructured":"Lapp, H. et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119, 2781\u20132788 (2009).","journal-title":"Circulation"},{"key":"1042_CR178","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani, H.-A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330\u2013340 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR179","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 382, 1883\u20131893 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR180","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1152\/ajprenal.00280.2004","volume":"288","author":"B Hohenstein","year":"2005","unstructured":"Hohenstein, B., Daniel, C., Wagner, A., Stasch, J. P. & Hugo, C. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. Am. J. Physiol. Renal Physiol. 288, 685\u2013693 (2005).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1042_CR181","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2215\/CJN.08410520","volume":"16","author":"JP Hanrahan","year":"2021","unstructured":"Hanrahan, J. P. et al. Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease a randomized placebo-controlled clinical trial. Clin. J. Am. Soc. Nephrol. 16, 59\u201369 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1042_CR182","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","volume":"40","author":"RT Gansevoort","year":"2025","unstructured":"Gansevoort, R. T. et al. The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial. Nephrol. Dial. Transplant. 40, 1147\u20131160\u00a0(2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1042_CR183","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","volume":"35","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials. J. Am. Soc. Nephrol. 35, 1227\u20131239 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1042_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04507061 (2023)."},{"key":"1042_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04736628 (2024)."},{"key":"1042_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04750577 (2024)."},{"key":"1042_CR187","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"SCW Tang","year":"2020","unstructured":"Tang, S. C. W. & Yiu, W. H. Innate immunity in diabetic kidney disease. Nat. Rev. Nephrol. 16, 206\u2013222 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR188","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","volume":"25","author":"MA Niewczas","year":"2019","unstructured":"Niewczas, M. A. et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat. Med. 25, 805\u2013813 (2019).","journal-title":"Nat. Med."},{"key":"1042_CR189","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12882-022-02794-8","volume":"23","author":"A Hofherr","year":"2022","unstructured":"Hofherr, A. et al. Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model. BMC Nephrol. 23, 208 (2022).","journal-title":"BMC Nephrol."},{"key":"1042_CR190","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle, K. R. et al. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrology Dialysis Transplant. 33, 1950\u20131959 (2018).","journal-title":"Nephrology Dialysis Transplant."},{"key":"1042_CR191","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","volume":"369","author":"Zeeuw","year":"2013","unstructured":"Zeeuw et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492\u20132503 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR192","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","volume":"15","author":"Z Chen","year":"2019","unstructured":"Chen, Z., Bozec, A., Ramming, A. & Schett, G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat. Rev. Rheumatol. 15, 9\u201317 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1042_CR193","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","volume":"43","author":"PM Ridker","year":"2022","unstructured":"Ridker, P. M., Tuttle, K. R., Perkovic, V., Libby, P. & MacFadyen, J. G. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur. Heart J. 43, 4832\u20134844 (2022).","journal-title":"Eur. Heart J."},{"key":"1042_CR194","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","volume":"71","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J. Am. Coll. Cardiol. 71, 2405\u20132414 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1042_CR195","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","volume":"117","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. From rescue to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc. Res. 117, e138\u2013e140 (2021).","journal-title":"Cardiovasc. Res."},{"key":"1042_CR196","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060\u20132069 (2021).","journal-title":"Lancet"},{"key":"1042_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05021835 (2025)."},{"key":"1042_CR198","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-022-01950-3","volume":"11","author":"S Madani","year":"2022","unstructured":"Madani, S. et al. Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis. Syst. Rev. 11, 82 (2022).","journal-title":"Syst. Rev."},{"key":"1042_CR199","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1380443","volume":"15","author":"UE Habiba","year":"2024","unstructured":"Habiba, U. E. et al. Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes. Front. Endocrinol. 15, 1380443 (2024).","journal-title":"Front. Endocrinol."},{"key":"1042_CR200","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","volume":"12","author":"DK Packham","year":"2016","unstructured":"Packham, D. K., Fraser, I. R., Kerr, P. G. & Segal, K. R. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine 12, 263\u2013269 (2016).","journal-title":"EBioMedicine"},{"key":"1042_CR201","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1001\/jama.2024.18581","volume":"332","author":"P Li","year":"2024","unstructured":"Li, P. et al. GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes. JAMA 332, 1667\u20131669 (2024).","journal-title":"JAMA"},{"key":"1042_CR202","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1111\/dom.15773","volume":"26","author":"MA Escobar Vasco","year":"2024","unstructured":"Escobar Vasco, M. A., Fantaye, S. H., Raghunathan, S. & Solis-Herrera, C. The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease. Diabetes Obes. Metab. 26, 4135\u20134146 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1042_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05822609 (2025)."},{"key":"1042_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06217302 (2025)."},{"key":"1042_CR205","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05901831 (2025)."},{"key":"1042_CR206","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","volume":"46","author":"K Marx-Sch\u00fctt","year":"2025","unstructured":"Marx-Sch\u00fctt, K. et al. Cardiovascular disease in chronic kidney disease. Eur. Heart J. 46, 2148\u20132160 (2025).","journal-title":"Eur. Heart J."},{"key":"1042_CR207","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1053\/j.ajkd.2009.02.012","volume":"53","author":"J Perl","year":"2009","unstructured":"Perl, J. & Bargman, J. M. The importance of residual kidney function for patients on dialysis: a critical review. Am. J. Kidney Dis. 53, 1068\u20131081 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"1042_CR208","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow, G. M. et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J. Am. Soc. Nephrol. 32, 2352\u20132361 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1042_CR209","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","volume":"42","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink, H. J. L. et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur. Heart J. 42, 1216\u20131227 (2021).","journal-title":"Eur. Heart J."},{"key":"1042_CR210","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05374291 (2025)."},{"key":"1042_CR211","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05614115 (2025)."},{"key":"1042_CR212","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05687058 (2025)."},{"key":"1042_CR213","doi-asserted-by":"publisher","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","volume":"5","author":"J-J Chen","year":"2022","unstructured":"Chen, J.-J. et al. Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. JAMA Netw. Open. 5, e221169\u2013e221169 (2022).","journal-title":"JAMA Netw. Open."},{"key":"1042_CR214","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06042153 (2025)."},{"key":"1042_CR215","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ekir.2025.01.007","volume":"10","author":"K Giri","year":"2025","unstructured":"Giri, K. & Dube, G. K. Is it time to expand the use of SGLT2 inhibitors in kidney transplant recipients? Kidney Int. Rep. 10, 660\u2013662 (2025).","journal-title":"Kidney Int. Rep."},{"key":"1042_CR216","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","volume":"42","author":"TAS Halden","year":"2019","unstructured":"Halden, T. A. S. et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42, 1067\u20131074 (2019).","journal-title":"Diabetes Care"},{"key":"1042_CR217","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/ajt.15223","volume":"19","author":"E Schwaiger","year":"2019","unstructured":"Schwaiger, E. et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am. J. Transpl. 19, 907\u2013919 (2019).","journal-title":"Am. J. Transpl."},{"key":"1042_CR218","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02649-0","volume":"24","author":"L-C Lin","year":"2025","unstructured":"Lin, L.-C., Chen, J.-Y., Huang, T. T.-M. & Wu, V.-C. Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients. Cardiovasc. Diabetol. 24, 87 (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"1042_CR219","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S2213-8587(24)00371-1","volume":"13","author":"BJ Orandi","year":"2025","unstructured":"Orandi, B. J. et al. GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol. 13, 374\u2013383\u00a0(2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1042_CR220","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1210\/clinem\/dgad177","volume":"108","author":"T Sato","year":"2023","unstructured":"Sato, T. et al. Possible advantage of glucagon-like peptide 1 receptor agonists for kidney transplant recipients with type 2 diabetes. J. Clin. Endocrinol. Metab. 108, 2597\u20132603 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1042_CR221","doi-asserted-by":"publisher","first-page":"sfae018","DOI":"10.1093\/ckj\/sfae018","volume":"17","author":"P Krisanapan","year":"2024","unstructured":"Krisanapan, P. et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis. Clin. Kidney J. 17, sfae018 (2024).","journal-title":"Clin. Kidney J."},{"key":"1042_CR222","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06731231 (2024)."},{"key":"1042_CR223","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04906213 (2025)."},{"key":"1042_CR224","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06140537 (2025)."},{"key":"1042_CR225","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06013865 (2025)."},{"key":"1042_CR226","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05788276 (2025)."},{"key":"1042_CR227","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06059664 (2025)."},{"key":"1042_CR228","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05702931 (2025)."},{"key":"1042_CR229","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05938712 (2025)."},{"key":"1042_CR230","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","volume":"400","author":"N Conrad","year":"2022","unstructured":"Conrad, N. et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400, 733\u2013743 (2022).","journal-title":"Lancet"},{"key":"1042_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152663","volume":"72 (Suppl.)","author":"A Kronbichler","year":"2025","unstructured":"Kronbichler, A. Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity. Semin. Arthritis Rheum. 72 (Suppl.), 152663(2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1042_CR232","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.kint.2017.11.034","volume":"93","author":"N Rabbani","year":"2018","unstructured":"Rabbani, N. & Thornalley, P. J. Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney Int. 93, 803\u2013813 (2018).","journal-title":"Kidney Int."},{"key":"1042_CR233","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/MNH.0000000000000062","volume":"23","author":"SK Mallipattu","year":"2014","unstructured":"Mallipattu, S. K. & Uribarri, J. Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease? Curr. Opin. Nephrol. Hypertens. 23, 547\u2013554 (2014).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1042_CR234","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/01.mjt.0000178769.52610.69","volume":"12","author":"MC Thomas","year":"2005","unstructured":"Thomas, M. C., Forbes, J. M. & Cooper, M. E. Advanced glycation end products and diabetic nephropathy. Am. J. Ther. 12, 562\u2013572 (2005).","journal-title":"Am. J. Ther."},{"key":"1042_CR235","doi-asserted-by":"publisher","first-page":"31S","DOI":"10.1016\/j.amjhyper.2004.08.021","volume":"17","author":"ME Cooper","year":"2004","unstructured":"Cooper, M. E. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am. J. Hypertens. 17, 31S\u201338S (2004).","journal-title":"Am. J. Hypertens."},{"key":"1042_CR236","doi-asserted-by":"publisher","first-page":"1128872","DOI":"10.3389\/fphar.2023.1128872","volume":"14","author":"K Taguchi","year":"2023","unstructured":"Taguchi, K. & Fukami, K. RAGE signaling regulates the progression of diabetic complications. Front. Pharmacol. 14, 1128872 (2023).","journal-title":"Front. Pharmacol."},{"key":"1042_CR237","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00592-018-1193-0","volume":"55","author":"M Li","year":"2018","unstructured":"Li, M. & Pezzolesi, M. G. Advances in understanding the genetic basis of diabetic kidney disease. Acta Diabetol. 55, 1093\u20131104 (2018).","journal-title":"Acta Diabetol."},{"key":"1042_CR238","doi-asserted-by":"publisher","first-page":"F1329","DOI":"10.1152\/ajprenal.00487.2016","volume":"311","author":"O Ruiz-Andres","year":"2016","unstructured":"Ruiz-Andres, O. et al. Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. Am. J. Physiol. Renal Physiol 311, F1329\u2013F1340 (2016).","journal-title":"Am. J. Physiol. Renal Physiol"},{"key":"1042_CR239","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165654","volume":"133","author":"S Mohandes","year":"2023","unstructured":"Mohandes, S. et al. Molecular pathways that drive diabetic kidney disease. J. Clin. Invest. 133, e165654 (2023).","journal-title":"J. Clin. Invest."},{"key":"1042_CR240","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10157-022-02181-5","volume":"26","author":"K Hayashi","year":"2022","unstructured":"Hayashi, K. Altered DNA methylation in kidney disease: useful markers and therapeutic targets. Clin. Exp. Nephrol. 26, 309\u2013315 (2022).","journal-title":"Clin. Exp. Nephrol."},{"key":"1042_CR241","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41581-023-00702-3","volume":"19","author":"JL Peek","year":"2023","unstructured":"Peek, J. L. & Wilson, M. H. Cell and gene therapy for kidney disease. Nat. Rev. Nephrol. 19, 451\u2013462 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1042_CR242","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3724\/abbs.2021016","volume":"54","author":"X Li","year":"2021","unstructured":"Li, X. et al. Epigenetics in the pathogenesis of diabetic nephropathy. Acta Biochim. Biophys. Sin. 54, 163\u2013172 (2021).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"1042_CR243","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.fct.2014.08.010","volume":"73","author":"S Khan","year":"2014","unstructured":"Khan, S. & Jena, G. Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-\u03b21-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem. Toxicol. 73, 127\u2013139 (2014).","journal-title":"Food Chem. Toxicol."},{"key":"1042_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101265","volume":"15","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Prioritization of potential drug targets for diabetic kidney disease using integrative omics data mining and causal inference. J. Pharm. Anal. 15, 101265\u00a0(2025).","journal-title":"J. Pharm. Anal."},{"key":"1042_CR245","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-020-00493-1","volume":"18","author":"MV Holmes","year":"2021","unstructured":"Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M. & Davey Smith, G. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat. Rev. Cardiol. 18, 435\u2013453 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"1042_CR246","doi-asserted-by":"publisher","first-page":"e2449998","DOI":"10.1001\/jamanetworkopen.2024.49998","volume":"7","author":"SS Kotwal","year":"2024","unstructured":"Kotwal, S. S. et al. The global kidney patient trials network and the captivate platform clinical trial design: a trial protocol. JAMA Netw. Open. 7, e2449998\u2013e2449998 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1042_CR247","doi-asserted-by":"publisher","first-page":"100927","DOI":"10.1016\/j.xkme.2024.100927","volume":"7","author":"P Singh","year":"2025","unstructured":"Singh, P. et al. Artificial intelligence in nephrology: clinical applications and challenges. Kidney Med. 7, 100927 (2025).","journal-title":"Kidney Med."},{"key":"1042_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48263-5","volume":"9","author":"M Makino","year":"2019","unstructured":"Makino, M. et al. Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning. Sci. Rep. 9, 11862 (2019).","journal-title":"Sci. Rep."},{"key":"1042_CR249","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1932296817706375","volume":"12","author":"A Dagliati","year":"2018","unstructured":"Dagliati, A. et al. Machine learning methods to predict diabetes complications. J. Diabetes Sci. Technol. 12, 295\u2013302 (2018).","journal-title":"J. Diabetes Sci. Technol."},{"key":"1042_CR250","unstructured":"Cha, T. et al. Machine learning systems and methods for predicting risk of renal function decline. US patent US20200005900A1 (2021)."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01042-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01042-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01042-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:02:21Z","timestamp":1776859341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01042-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":250,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-01042-0","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"28 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.W.Y. has received conference and travel support from Lexicon Pharmaceuticals and Boehringer Ingelheim. V.S.S. has received conference and travel support from Merck Canada and Lexicon Pharmaceuticals and received advisory board fees from Novo Nordisk Canada. J.S. has received speaker fees from CSL Vifor. M.N. declares no competing interests. D.C reports serving or having served as a consultant for Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometric, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK and Novo-Nordisk. He has received operational funding from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo-Nordisk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}